Fludarabine
Kidney Cancer
National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 73/ 100
Competitive context
70 Active assets in the Kidney Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alpha-Interferon Dartmouth-Hitchcock Medical Center | Phase 3 | BBB |
Girentuximab Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
Girentuximab Heidelberg Pharma AG | Phase 3 | BB |
ETOPOSIDE City of Hope Medical Center | Phase 3 | BB |
FLUOROURACILUM Medical Research Council | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →